- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04544007
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas (NF111)
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
Study Overview
Detailed Description
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy.
The secondary objectives are to:
- Determine 12, 24 and 60 month progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC.
- Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by best objective tumor response rate (CR+PR) within 24 cycles of therapy.
- Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by clinical benefit response rate (CR+PR+MR+SD) after 12 and 24 cycles of therapy.
- Assess the toxicity associated with poly-ICLC treatment in pediatric NF1 patients with LGG.
Exploratory objectives are to:
- Evaluate the visual outcome measures in children with progressive optic pathway gliomas treated with poly-ICLC. Visual response is defined as 0.2 logMAR or greater in acuity improvement.
- Evaluate patient reported outcomes and quality of life measures.
- Evaluate biological correlates.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Bruce R Korf, MD, PhD
- Phone Number: 205.934.9410
- Email: bkorf@uabmc.edu
Study Contact Backup
- Name: Karen A Cole-Plourde, BS
- Phone Number: 205.934.5140
- Email: kplourde@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- The University of Alabama at Birmingham (Site 700)
-
Principal Investigator:
- Bruce Korf, MD, PhD
-
Contact:
- Katie Metrock, MD
- Phone Number: 205-638-6945
- Email: lmetrock@uabmc.edu
-
Contact:
- Brian Roberts
- Phone Number: 205-638-5449
- Email: brianroberts@uabmc.edu
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital of Los Angeles
-
Contact:
- Tena Rosser, MD
- Phone Number: 323-361-2471
- Email: trosser@chla.usc.edu
-
Contact:
- Patricia Diaz
- Phone Number: 323-361-7319
- Email: padiaz@chla.usc.edu
-
Principal Investigator:
- Tena Rosser, MD
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Children's National Medical Center (Site 775)
-
Contact:
- Roger Packer, MD
- Phone Number: 202-476-5997
- Email: RPacker@childrensnational.org
-
Contact:
- Elizabeth Krisanda
- Phone Number: (202) 476-6551
- Email: EKrisanda@childrensnational.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Children's Healthcare of Atlanta
-
Contact:
- Dolly Aguilera, MD
- Phone Number: 404-785-3598
- Email: dolly.aguilera@choa.org
-
Contact:
- Olivia Floyd
- Phone Number: 404-785-0232
- Email: Olivia.floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Children's Lurie Hospital
-
Contact:
- Angela Waanders, MD
- Phone Number: 312-227-4939
- Email: awaanders@luriechildrens.org
-
Chicago, Illinois, United States, 60611
- Recruiting
- Lurie Children's Hospital of Chicago (Site 350)
-
Contact:
- Angela Waanders, MD
- Phone Number: 312-227-4939
- Email: awaanders@luriechildrens.org
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago (Site 850)
-
Contact:
- James Tonsgard, MD
- Phone Number: 773-203-2344
- Email: jtonsgar@peds.bsd.uchicago.edu
-
Contact:
- Cynthia MacKenzie, RN, BSN
- Phone Number: 773-203-2344
- Email: cmackenzie@peds.bsd.uchicago.edu
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University - St. Louis (Site 900)
-
Contact:
- Amy Armstrong, MD
- Phone Number: 314-454-6018
- Email: armstrongae@wustl.edu
-
-
New York
-
New York, New York, United States, 10016
- Not yet recruiting
- New York University Medical Center (Site 200)
-
Contact:
- Anna Yaffe
- Phone Number: 212-263-9945
- Email: anna.yaffe@nyumc.org
-
Contact:
- Kaleb Yohay, MD
- Phone Number: 212-263-7744
- Email: kaleb.yohay@nyumc.org
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Recruiting
- Cincinnati Children's Hospital Medical Center (Site 800)
-
Contact:
- Peter de Blank, MD
- Phone Number: 513-517-2068
- Email: Peter.deBlank@cchmc.org
-
Contact:
- Lori Backus, BA, CCRP
- Phone Number: 513.636.2047
- Email: Lori.backus@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19096
- Recruiting
- Children's Hospital of Philadelphia (Site 750)
-
Contact:
- Michael Fisher, MD
- Phone Number: 215-590-2800
- Email: fisherm@email.chop.edu
-
Contact:
- Ratnakar Patti
- Phone Number: 267.426.5503
- Email: pattir@email.chop.edu
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- Childrens Medical Center - Univ. of Texas SW (Site 917)
-
Contact:
- Laura Klesse, MD, PhD
- Phone Number: 214-456-3727
- Email: Laura.Klesse@utsouthwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: Patients must be less than 22 years at the time of enrollment; there is no lower age limit.
- All participants must have an identified pathogenetic constitutional NF1 mutation OR the clinical diagnosis of NF1 using the NIH Consensus Conference criteria.
- Diagnosis: LGG (WHO Grade 1 and 2) of the brain and spinal cord are eligible. Histologic confirmation of tumor is not necessary in the presence of consistent clinical and radiographic findings. Biopsy for histologic diagnosis is required if there is clinical suspicion for a high-grade tumor; special attention is recommended in older adolescents or young adults to the potential for malignant transformation. Patients with metastatic disease are eligible.
Patients must meet at least one of the following criteria for progression or recurrence of a previously treated target tumor:
- Progression or recurrence on MRI.
- New or worsening neurologic symptoms attributable to the target tumor.
- For patients with OPG: visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year by examination or history, attributable to tumor.
- Measurable Disease: Patients must have two-dimensional measurable tumor >1cm2.
- Prior Therapy: Patients must have had at least one prior medical treatment for the target LGG.
- Performance Level: Patients must have a performance status of equal or > than 50 using Karnofsky for patients equal or ≥ 16 years of age and Lansky for patients < 16 years of age.
Patients must have recovered to grade ≤1 from any acute toxicities from all prior treatments. to enroll on this study and meet time restrictions from end of prior therapy as defined below:
- Myelosuppressive chemotherapy: must have received the last dose of myelosuppressive therapy at least 4 weeks prior to study registration, or at least 6 weeks if nitrosourea.
- Investigational/biological agent: Patient must have received the last dose of other investigational, immunotherapy, or biological agent > 14 days prior to study registration or at least 5 half-lives, whichever is greater. Bevacizumab last dose > 36 days prior to enrollment.
- Radiation therapy: Patients SHOULD NOT have received prior irradiation.
- Study specific limitations on prior therapy: There is no limit on the number of prior treatment regimens.
- Growth factor(s): Must not have received any hematopoietic growth factors within 7 days of study entry or > 14 days if pegylated GCSF is used.
- Prior surgery: At the time of enrollment, must be ≥ 3 weeks from prior major surgery such as craniotomy, orthopedic surgery, abdominal surgery or ≥1 week from minor surgery and completely recovered. Port or central line placement is not considered a major surgery.
Organ Function Requirements:
All patients must have adequate organ function defined as:
9.1 Hematologic Function:
- Hemoglobin: > 8.0 gm/dl (may transfuse PRBCs)
- ANC: > 750/mm3. Must be at least 7 days after last dose of growth factor or > 14 days since last dose of pegylated GCSF
- Platelet Count: > 75,000/mm3 (transfusion independent; ≥ 7 days from last transfusion)
9.2 Renal Function: Serum creatinine which is less than 1.5 times ULN for age (as per the table below) or GFR > 70 ml/min/1.73m2
Renal Function Normal for Age
Age Maximum Serum Creatinine (mg/dL) Male Female 1 month to < 6 months 0.4 0.4 6 months to < 1 year 0.5 0.5 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4
≥ 16 years 1.7 1.4
Liver Function:
- Total bilirubin < 1.5 x ULN (Children with diagnosis of Gilbert's Syndrome will be allowed on the study regardless of their total and indirect bilirubin levels as long as the direct bilirubin is less than 3.1 mg/dL.)
- SGPT (ALT) ≤ 5 x ULN
- SGOT (AST) ≤ 5 x ULN
Pulmonary Function:
No evidence of dyspnea at rest, and a pulse oximetry ≥ 92%.
Reproductive Function:
Female patients of childbearing potential must have negative serum or urine pregnancy test within 7 days prior to the first dose of poly-ICLC. Patient must not be pregnant or breast-feeding. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, including abstinence, while being treated on this study and for 90 days following cessation of treatment.
- Patient is able to start treatment within 7 days after enrollment.
- Patients with neurological deficits must be stable for a minimum of 1 week prior to enrollment.
- Patients are only eligible if complete resection of the LGG with acceptable morbidity is not feasible, or if a patient with a surgical option refuses surgery.
- Parents/legal guardians must provide written informed consent and agree that they will comply with the study.
Exclusion Criteria:
- Prior radiation treatment for the low-grade glioma.
- Prior exposure to poly-ICLC.
- Patients currently receiving other anti-tumor therapy or experimental therapy (targeted agents, chemotherapy radiation).
- Patients with a current or prior diagnosis of malignant glioma (WHO grade III or IV).
- Patients with a prior diagnosis of malignant peripheral nerve sheath tumor or other malignancy requiring treatment in the last 48 months.
- Patients may not have fever (≥38.50 C) within 3 days of enrollment.
- Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Active auto-immune illness.
- Pregnant or lactating females.
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 90 days after stopping study therapy are not eligible.
- Severe unresolved infection that requires systemic IV antibiotics.
- Patients with any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, impaired gastrointestinal function, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients requiring high doses of steroids. Patients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as ≤ 0.75 mg/m2/day dexamethasone or equivalent) at time of enrollment. However, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administer Poly-ICLC
Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
|
Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the efficacy of poly-ICLC
Time Frame: First 48 weeks
|
evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR)
|
First 48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine progression free survival (PFS)
Time Frame: 12 Months
|
a) Determine progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC.
|
12 Months
|
Determine progression free survival (PFS)
Time Frame: 24 Months
|
a) Determine progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC.
|
24 Months
|
Determine progression free survival (PFS)
Time Frame: 60 Months
|
a) Determine progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC.
|
60 Months
|
Evaluate efficacy by best objective tumor response rate (CR+PR)
Time Frame: 24 Months
|
b) Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by best objective tumor response rate (CR+PR).
|
24 Months
|
Evaluate efficacy by clinical benefit response rate (CR+PR+MR+SD)
Time Frame: 12 Months
|
c) Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by clinical benefit response rate (CR+PR+MR+SD).
|
12 Months
|
Evaluate efficacy by clinical benefit response rate (CR+PR+MR+SD)
Time Frame: 24 Months
|
c) Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by clinical benefit response rate (CR+PR+MR+SD).
|
24 Months
|
Assess toxicity
Time Frame: Up to 60 months
|
d) Assess the toxicity associated with poly-ICLC treatment in pediatric NF1 patients with LGG.
|
Up to 60 months
|
Collaborators and Investigators
Investigators
- Study Director: Juliette Southworth, BS, CCRP, University of Alabama at Birmingham, NFCTC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- W81XWH-17-2-0037 (CDMRP of the Dept. of Defense, US Army)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low-grade Glioma
-
National Cancer Institute (NCI)RecruitingLow Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade GliomaUnited States, Canada, Puerto Rico
-
St. Jude Children's Research HospitalSpringWorks Therapeutics, Inc.RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Neurological Associates of West Los AngelesEnrolling by invitationLow Grade Glioma of BrainUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | WHO Grade 3 Glioma With IDH1 Mutation | WHO Grade 3 Glioma With 1p/19q CodeletionUnited States
Clinical Trials on Poly ICLC
-
Shanghai 10th People's HospitalHangzhou NeoVax Biotechnology Co. LTDRecruitingGlioma, Malignant | Antigen-specific Vaccines | Individualized TreatmentChina
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Smallpox | Ebola | Severe Acute Respiratory Distress Syndrome | Unknown Respiratory VirusesUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
Nevada Cancer InstituteCLL TopicsTerminatedB Cell Lymphoma | T Cell LymphomaUnited States
-
Rockefeller UniversityCompletedHealthy VolunteersUnited States
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
Ashutosh Kumar TewariOncovir, Inc.Completed
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Nina BhardwajOncovir, Inc.TerminatedMelanoma | Breast Cancer | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Skin | Sarcoma of the Skin | Basal Cell Cancer of the SkinUnited States
-
Medical University of South CarolinaCompletedA Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Non-resectableUnited States